|
1
|
Grade M, Wolff HA, Gaedcke J and Ghadimi
BM: The molecular basis of chemoradiosensitivity in rectal cancer:
Implications for personalized therapies. Langenbecks Arch Surg.
397:543–555. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vogelstein B and Kinzler KW: Cancer genes
and the pathways they control. Nat Med. 10:789–799. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Woynarowska BA, Roberts K, Woynarowski JM,
MacDonald JR and Herman TS: Targeting apoptosis by
hydroxymethylacylfulvene in combination with gamma radiation in
prostate tumor cells. Radiat Res. 154:429–438. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wiley SR, Schooley K, Smolak PJ, Din WS,
Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA,
et al: Identification and characterization of a new member of the
TNF family that induces apoptosis. Immunity. 3:673–682. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Perlstein B, Finniss SA, Miller C,
Okhrimenko H, Kazimirsky G, Cazacu S, Lee HK, Lemke N, Brodie S,
Umansky F, et al: TRAIL conjugated to nanoparticles exhibits
increased anti-tumor activities in glioma cells and glioma stem
cells in vitro and in vivo. Neuro Oncol. 15:29–40. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tucker-Kellogg L, Shi Y, White JK and
Pervaiz S: Reactive oxygen species (ROS) and sensitization to
TRAIL-induced apoptosis, in Bayesian network modelling of HeLa cell
response to LY303511. Biochem Pharmacol. 84:1307–1317. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Niemoeller OM and Belka C: Radiotherapy
and TRAIL for cancer therapy. Cancer Lett. 332:184–193. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li YB, Guo CX, Wang ZC, Dong LH, Guan F,
Liu Y, Wang HF, Sun ZW and Gong SL: Radiosensitization of breast
cancer cells by TRAIL-endostatin-targeting gene therapy. Neoplasma.
60:613–619. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mahalingam D, Szegezdi E, Keane M, de Jong
S and Samali A: TRAIL receptor signalling and modulation: Are we on
the right TRAIL? Cancer Treat Rev. 35:280–288. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sprick MR, Rieser E, Stahl H, Grosse-Wilde
A, Weigand MA and Walczak H: Caspase-10 is recruited to and
activated at the native TRAIL and CD95 death-inducing signalling
complexes in a FADD-dependent manner but can not functionally
substitute caspase-8. EMBO J. 21:4520–4530. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Datta R, Rubin E, Sukhatme V, Qureshi S,
Hallahan D, Weichselbaum RR and Kufe DW: Ionizing radiation
activates transcription of the EGR1 gene via CArG elements. Proc
Natl Acad Sci USA. 89:10149–10153. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Weichselbaum RR, Hallahan DE, Sukhatme VP
and Kufe DW: Gene therapy targeted by ionizing radiation. Int J
Radiat Oncol Biol Phys. 24:565–567. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu LL, Smith MJ, Sun BS, Wang GJ, Redmond
HP and Wang JH: Combined IFN-gamma-endostatin gene therapy and
radiotherapy attenuates primary breast tumor growth and lung
metastases via enhanced CTL and NK cell activation and attenuated
tumor angiogenesis in a murine model. Ann Surg Oncol. 16:1403–1411.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang W and Li XY: Anti-tumor effect of
pEgr-interferon-γ-endostatin gene-radiotherapy in mice bearing
Lewis lung carcinoma and its mechanism. Chin Med J (Engl).
118:296–301. 2005.PubMed/NCBI
|
|
15
|
Li ZL, Liang S, Wang ZC, Li YB, Guo CX,
Fang F, Gong SL and Lin CH: Expression of Smac induced by the Egr1
promoter enhances the radiosensitivity of breast cancer cells.
Cancer Gene Ther. 21:142–149. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Weichselbaum RR, Kufe DW, Advani SJ and
Roizman B: Molecular targeting of gene therapy and radiotherapy.
Acta Oncol. 40:735–738. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pines A, Bivi N, Romanello M, Damante G,
Kelley MR, Adamson ED, D'Andrea P, Quadrifoglio F, Moro L and Tell
G: Cross-regulation between Egr-1 and APE/Ref-1 during early
response to oxidative stress in the human osteoblastic HOBIT cell
line: Evidence for an autoregulatory loop. Free Radic Res.
39:269–281. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang WD, Chen ZT, Li R, Li DZ, Duan YZ and
Cao ZH: Enhanced efficacy of radiation-induced gene therapy in mice
bearing lung adenocarcinoma xenografts using hypoxia responsive
elements. Cancer Sci. 96:918–924. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Greco O, Joiner MC, Doleh A, Powell AD,
Hillman GG and Scott SD: Hypoxia- and radiation-activated Cre/loxP
‘molecular switch’ vectors for gene therapy of cancer. Gene Ther.
13:206–215. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Donadelli M, Pozza E Dalla, Scupoli MT,
Costanzo C, Scarpa A and Palmieri M: Intracellular zinc increase
inhibits p53(−/−) pancreatic adenocarcinoma cell growth by
ROS/AIF-mediated apoptosis. Biochim Biophys Acta. 1793:273–280.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pauwels B, Korst AE, de Pooter CM, Pattyn
GG, Lambrechts HA, Baay MF, Lardon F and Vermorken JB: Comparison
of the sulforhodamine B assay and the clonogenic assay for in vitro
chemoradiation studies. Cancer Chemother Pharmacol. 51:221–226.
2003.PubMed/NCBI
|
|
22
|
Ding M, Li R, He R, Wang X, Yi Q and Wang
W: p53 activated by AND gate genetic circuit under radiation and
hypoxia for targeted cancer gene therapy. Cancer Sci.
106:1163–1173. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cao XM, Koski RA, Gashler A, McKiernan M,
Morris CF, Gaffney R, Hay RV and Sukhatme VP: Identification and
characterization of the Egr-1 gene product, a DNA-binding zinc
finger protein induced by differentiation and growth signals. Mol
Cell Biol. 10:1931–1939. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Min FL, Zhang H and Li WJ: Current status
of tumor radiogenic therapy. World J Gastroenterol. 11:3014–3019.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bickenbach KA, Veerapong J, Shao MY,
Mauceri HJ, Posner MC, Kron SJ and Weichselbaum RR: Resveratrol is
an effective inducer of CArG-driven TNF-alpha gene therapy. Cancer
Gene Ther. 15:133–139. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Brown JM and Wilson WR: Exploiting tumour
hypoxia in cancer treatment. Nat Rev Cancer. 4:437–447. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang TJ and Ho AY: Radiation therapy in
the management of breast cancer. Surg Clin North Am. 93:455–471.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Seol JY, Park KH, Hwang CI, Park WY, Yoo
CG, Kim YW, Han SK, Shim YS and Lee CT: Adenovirus-TRAIL can
overcome TRAIL resistance and induce a bystander effect. Cancer
Gene Ther. 10:540–548. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hu Y, Ouyang W, Wu F, Cao CH, Wang K, Liao
ZK, Zhong YH, Zhou FX, Liu SQ, Xia L, et al: Enhanced
radiosensitivity of SW480 cells via TRAIL up-regulation mediated by
Egr-1 promoter. Oncol Rep. 22:765–771. 2009.PubMed/NCBI
|
|
30
|
Cheng G, Kong D, Hou X, Liang B, He M,
Liang N, Ma S and Liu X: The tumor suppressor, p53, contributes to
radiosensitivity of lung cancer cells by regulating autophagy and
apoptosis. Cancer Biother Radiopharm. 28:153–159. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pauwels B, Korst AE, de Pooter CM, Pattyn
GG, Lambrechts HA, Baay MF, Lardon F and Vermorken JB: Comparison
of the sulforhodamine B assay and the clonogenic assay for in vitro
chemoradiation studies. Cancer Chemother Pharmacol. 51:221–226.
2003.PubMed/NCBI
|
